Immuno-Biological Laboratories Past Earnings Performance
Past criteria checks 0/6
Immuno-Biological Laboratories has been growing earnings at an average annual rate of 13.2%, while the Life Sciences industry saw earnings growing at 28.2% annually. Revenues have been growing at an average rate of 3.3% per year.
Key information
13.2%
Earnings growth rate
14.8%
EPS growth rate
Life Sciences Industry Growth | 32.0% |
Revenue growth rate | 3.3% |
Return on equity | -17.6% |
Net Margin | -24.5% |
Next Earnings Update | 14 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Immuno-Biological Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 788 | -193 | 259 | 179 |
30 Sep 23 | 866 | -127 | 262 | 179 |
30 Jun 23 | 815 | -220 | 280 | 179 |
31 Mar 23 | 794 | -289 | 295 | 179 |
31 Dec 22 | 753 | -91 | 271 | 188 |
30 Sep 22 | 687 | -195 | 276 | 188 |
30 Jun 22 | 678 | -206 | 282 | 188 |
31 Mar 22 | 647 | -258 | 310 | 188 |
31 Dec 21 | 636 | -258 | 249 | 267 |
30 Sep 21 | 608 | -287 | 278 | 267 |
30 Jun 21 | 611 | -299 | 300 | 267 |
31 Mar 21 | 602 | -318 | 320 | 267 |
31 Dec 20 | 601 | -634 | 461 | 318 |
30 Sep 20 | 593 | -644 | 478 | 318 |
30 Jun 20 | 579 | -673 | 498 | 318 |
31 Mar 20 | 576 | -668 | 494 | 318 |
31 Dec 19 | 592 | -428 | 472 | 236 |
30 Sep 19 | 627 | -376 | 457 | 236 |
30 Jun 19 | 723 | -247 | 419 | 236 |
31 Mar 19 | 781 | -167 | 397 | 236 |
31 Dec 18 | 832 | -60 | 400 | 173 |
30 Sep 18 | 809 | -57 | 367 | 173 |
30 Jun 18 | 797 | -35 | 355 | 173 |
31 Mar 18 | 758 | -52 | 352 | 173 |
31 Dec 17 | 734 | -1,963 | 212 | 1,239 |
30 Sep 17 | 724 | -2,023 | 255 | 1,239 |
30 Jun 17 | 733 | -2,093 | 311 | 1,239 |
31 Mar 17 | 741 | -2,094 | 311 | 1,239 |
31 Dec 16 | 744 | -195 | 374 | 193 |
30 Sep 16 | 796 | -103 | 334 | 193 |
30 Jun 16 | 733 | -113 | 303 | 193 |
31 Mar 16 | 717 | -31 | 313 | 193 |
31 Dec 15 | 782 | -47 | 350 | 159 |
30 Sep 15 | 715 | -116 | 380 | 159 |
30 Jun 15 | 735 | -76 | 365 | 159 |
31 Mar 15 | 729 | -158 | 348 | 159 |
31 Dec 14 | 665 | -130 | 337 | 152 |
30 Sep 14 | 710 | -56 | 295 | 152 |
30 Jun 14 | 681 | -115 | 305 | 152 |
31 Mar 14 | 670 | -114 | 291 | 152 |
Quality Earnings: 4570 is currently unprofitable.
Growing Profit Margin: 4570 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4570 is unprofitable, but has reduced losses over the past 5 years at a rate of 13.2% per year.
Accelerating Growth: Unable to compare 4570's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4570 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-19.3%).
Return on Equity
High ROE: 4570 has a negative Return on Equity (-17.56%), as it is currently unprofitable.